X4 Pharmaceuticals, Inc.
XFOR
$3.53
$0.030.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.81M | 2.71M | 2.57M | 1.77M | 1.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.81M | 2.71M | 2.57M | 1.77M | 1.97M |
| Cost of Revenue | 1.62M | 598.00K | 364.00K | 351.00K | 326.00K |
| Gross Profit | 7.19M | 2.11M | 2.20M | 1.41M | 1.65M |
| SG&A Expenses | 8.50M | 6.93M | 7.38M | 8.19M | 9.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.20M | 22.98M | 26.47M | 24.37M | 28.21M |
| Operating Income | -16.39M | -20.27M | -23.90M | -22.61M | -26.23M |
| Income Before Tax | -16.16M | -20.24M | -23.93M | -29.85M | -25.70M |
| Income Tax Expenses | 2.00K | -- | 0.00 | -30.00K | 37.00K |
| Earnings from Continuing Operations | -16.16M | -20.24M | -23.93M | -29.82M | -25.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.16M | -20.24M | -23.93M | -29.82M | -25.74M |
| EBIT | -16.39M | -20.27M | -23.90M | -22.61M | -26.23M |
| EBITDA | -15.39M | -20.05M | -23.68M | -22.39M | -25.88M |
| EPS Basic | -0.13 | -0.16 | -0.43 | -0.69 | -3.47 |
| Normalized Basic EPS | -0.08 | -0.10 | -0.27 | -0.36 | -2.17 |
| EPS Diluted | -0.13 | -0.16 | -0.43 | -0.69 | -3.47 |
| Normalized Diluted EPS | -0.08 | -0.10 | -0.27 | -0.36 | -2.17 |
| Average Basic Shares Outstanding | 126.34M | 126.29M | 111.44M | 43.27M | 7.41M |
| Average Diluted Shares Outstanding | 126.34M | 126.29M | 111.44M | 43.27M | 7.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |